Posted by Michael Wonder on 14 Oct 2019
U.S. FDA approves Xarelto (rivaroxaban) to help prevent blood clots in acutely ill medical patients
14 October 2019 - Xarelto provides a new oral option to help prevent venous thromboembolism (VTE) and VTE-related death during hospitalisation and post-hospital discharge in acutely ill medical patients at risk for VTE and not at high risk of bleeding.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. FDA has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding. With the approval of this new indication, Xarelto can be initiated for these patients during hospitalisation and continued after discharge for a total recommended duration of 31 to 39 days.
More than 20,000 patients with acute medical illnesses were evaluated in the Phase 3 clinical program, which includes the MAGELLAN and MARINER studies.
